How do DNA cutting errors lead to relapsed childhood leukaemia
Looking at how a process called 'cut-and-run' leads to genetic errors, and how those errors could be prevented in order to prevent relapse in childhood leukaemia.
Creating a new immunotherapy approach to fight aggressive medulloblastoma
Finding a way to use immunotherapy against a high-risk type of childhood brain tumour.
Blocking chemical reactions which keep ependymoma cells alive
Testing four medicines to see if they can shut down the metabolism of brain cancer cells grown in the lab
Stopping drug resistant processes in T-cell acute lymphoblastic leukaemia
Developing a test to select patients who can be treated with a new medicine that prevents steroid resistance.
Repurposing alcohol-abuse medicines to treat brain tumours
Understanding how a repurposed drug attacks and kills diffuse midline glioma cells.
Blocking processes which keep leukaemia cells alive
Investigating the possibility of combining a medicine that blocks the process with a medicine that triggers a cell's defensive response to treat ALL.
Identifying new drugs for the treatment of retinoblastoma
Testing new targeted drugs for retinoblastoma to find new treatment options.
Testing existing drugs in new combinations for high-risk neuroblastoma
Testing whether a combination of drugs could reduce the risk of relapse and limit side effects.
The glowing tumour trial for children with aggressive brain tumours
A clinical trial testing the use of the 'pink drink' dye in children with brain tumours.